Duvelisib (IPI-145)

For research use only.

Catalog No.S7028 Synonyms: INK1197

32 publications

Duvelisib (IPI-145) Chemical Structure

CAS No. 1201438-56-3

Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.

Selleck's Duvelisib (IPI-145) has been cited by 32 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.
Targets
PI3Kδ [1]
(Cell-free assay)
PI3Kβ [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
23 pM(Ki) 1564 pM(Ki) 243 pM(Ki)
In vitro

IPI-145 suppresses murine/human B-cell proliferation with EC50 of 0.5 nM/0.5 nM and also inhibits human T-cell proliferation with EC50 of 9.5 nM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jurkat MWjQdo9tcW[ncnH0bY9vKGG|c3H5 NXTOT4ZHOyCmYYnz NXnOPZpjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKeZJs[XRiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUC9NU46KM7ebR?= NYXJ[WVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=>
MOLT4 Mkj2VJJwdGmoZYLheIlwdiCjc4PhfS=> NFPrWmo{KGSjeYO= M4ryVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGlEPTB;Mj6zJO69VQ>? Moj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxNlcoRjJ5N{e0NVI4RC:jPh?=
MV4-11 M{Doc3Bzd2yrZnXyZZRqd25iYYPzZZk> NHnzTmE{KGSjeYO= M3T0NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyPUSuOEDPxE1? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
MOLM14 NXPlc|ZbWHKxbHnm[ZJifGmxbjDhd5NigQ>? MmTlN{Bl[Xm| NV;jWoNuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTRiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUC9NU4zKM7:TR?= M4X4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
Loucy M1m2SXBzd2yrZnXyZZRqd25iYYPzZZk> NUDMcYlbOyCmYYnz MkTZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb4XjfUBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OD1yLkm4JO69VQ>? NVzEZVk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=>
JURKAT NEXiPFBHfW6ldHnvckBie3OjeR?= MlvnNE4yNCBzLkCsJIFv\CB7LkCg{txO NEfPVmZKWElzNEWge4F{KGGkbHWgeI8hcW6qaXLpeEBCc3RiYX7kJHM3KHCqb4PwbI9zgWyjdHnvckBidmRibX;k[ZN1dHliYX\m[YN1\WRiZ4Lve5RpKGmwIFrVVmtCXA>? MmnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7N{CyOlMoRjNyOUewNlY{RC:jPh?=
MOLT3 NUHoSlEyTnWwY4Tpc44h[XO|YYm= MUKwMlEtKDFwMDygZY5lKDlwMDFOwG0> NEDPZ5NKWElzNEWge4F{KGGkbHWgeI8hcW6qaXLpeEBCc3RiYX7kJHM3KHCqb4PwbI9zgWyjdHnvckBjfXRiYnHy[Yx6KGGoZnXjeIVlKHSqZTDndo94fGhib3[gUW9NXDNiVD3BUGw> NWfNWlIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5O|AzPjNpPkOwPVcxOjZ|PD;hQi=>
Raji32 MVrGeY5kfGmxbjDhd5NigQ>? NInw[JAyKM7:TR?= MYjl[oZm[3SrdnXsfUBqdXCjaYLl[EB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> M2HzfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUi0NlU1Lz5|MEW4OFI2PDxxYU6=
Ramos460 MnrXSpVv[3Srb36gZZN{[Xl? NIDIb2oyKM7:TR?= M1fte4Vn\mWldHn2[Yx6KGmvcHHpdoVlKHSqZTDwbI9{eGixconsZZRqd25ib3[gRYt1 MlLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OESyOVQoRjNyNUi0NlU1RC:jPh?=
HBL-1 Mk\ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEjqNndIUTVyPUWuN{DPxE1? MnXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
OCI-Ly3 MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPGN5NNT0l3ME2zMlch|ryP M3PxUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
TMD-8 M2nOVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXrGcnJ{T0l3ME2wMlAxODVizszN MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB4N{e3NUc,OzByNke3O|E9N2F-
U-2932 M3XxeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUnHTVUxRTFwODFOwG0> NHHkW|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
Farage MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYrJcINDT0l3ME2wMlA1KM7:TR?= M2fPRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
SU-DHL-10 MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHjrcZJIUTVyPUKuOEDPxE1? NIXKWmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
SU-DHL-4 MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFTDeYZIUTVyPUCuNkDPxE1? MoOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
Karpas-422 Mo\YS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1SyS2dKPTB;MD6xJO69VQ>? NVuyT4YxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
DOHH-2 M1HMemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIP3RYxIUTVyPUCuNFUh|ryP M2\ublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
WSU-NHL MmC5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfHTVUxRTBwMEC4JO69VQ>? M13SUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
Jeko-1 MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3;lZ2dKPTB;MT6zJO69VQ>? NVS1cFZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
Mino NWP1VWRpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2[wNmdKPTB;Mz60JO69VQ>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB4N{e3NUc,OzByNke3O|E9N2F-
NCI-H929 NF\yWWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGfWe|dIUTVyPUGg{txO M3;MblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
HH NF3zfZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NI\Mdo1IUTVyPUCuNFEh|ryP NGPadm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
BJAB NIrFTXVE\WyuII\pZYJqdGm2eTDhd5NigQ>? MnPUNE4yNCBzLDC1JO69VQ>? NEn2UZk1QCCjbnSgO|IhcA>? M2XW[olvcGmkaYTl[EBk\WyuIHfyc5d1cA>? MnH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MkKyO|goRjJ7NUKyNlc5RC:jPh?=
LCL MUHD[YxtKH[rYXLpcIl1gSCjc4PhfS=> M{fTXVAvOSxiMTygOUDPxE1? NF\LdVM1QCCjbnSgO|IhcA>? Ml3tbY5pcWKrdHXkJINmdGxiZ4Lve5Rp M361RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUKyNlc5Lz5{OUWyNlI4QDxxYU6=
insect cells MorCSpVv[3Srb36gZZN{[Xl? MkHzOUBucW6| M1\IemlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iQz30[ZJucW6jbDDIbZM3NXSjZ3fl[EBxOTFyZ3HtcYEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{B2e2mwZzDwbI9{eGijdHnkfYxqdm:|aYTvcEBieyC|dXLzeJJifGViaX6gdJJme2WwY3Wgc4Yh\2GvbXGtN|JRNUGWUDDh[pRmeiB3IH3pcpMh[nlidHjpckBt[XmncjDjbJJwdWG2b3fyZZBpcWNibXX0bI9lNCCLQ{WwJF0hOC5zIN88UU4> NXXrTnRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzB|OUWwNk8oRkOqRV3CUFww[T5?
Sf21 Ml;FSpVv[3Srb36gZZN{[Xl? MlvKOUBucW6| MorMTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKHBzMUDk[Yx1[S:3boTh[4dm\CC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBxQDWjbIDoZUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSClZXzsd{B2e2mwZzDwbI9{eGijdHnkfYxqdm:|aYTvcEBieyC|dXLzeJJifGViaX6gdJJme2WwY3Wgc4Yh\2GvbXGtN|JRNUGWUDDh[pRmeiB3IH3pcpMh[nlidHjpckBtNCCLQ{WwJF0hOC5zIN88UU4> NHTUVHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{ODN7NUCyM{c,S2iHTVLMQE9iRg>?
splenic B NXPnbY92SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MnuyN|AhdWmwcx?= NVX6dphpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBD[WykL3OgcY92e2Vic4Ds[Y5q[yCEIHPlcIx{KHC{ZXnuZ5Vj[XSnZDDmc5IhOzBibXnud{Bnd2yub4fl[EBjgSCOUGOgc5IhTiijYjepNkBld26tZYmgZY51cS2vb4Xz[UBK\01iYX7kJJJm[2:vYnnuZY51KG2xdYPlJGlNPCC|dHnteYxifGmxbjDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliQXzhcYFzKEKudXWgdoVlfWO2aX;uJIF{e2G7LDDFR|UxKD1iMD6xJO69VS5? M1vvS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMxOzl3MEKvK|5EcEWPQly8M4E,
Sf21 MlXoSpVv[3Srb36gZZN{[Xl? MlK4OUBucW6| MV7Jcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4heDFzMHLleIEwfW62YXfn[YQhemWlb33ibY5idnRiZoXscEBt\W6pdHigdFg2[WyyaHGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIGPmNlEh[2WubIOgeZNqdmdicHjvd5Bp[XSrZInsbY5we2m2b3ygZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJIdidW2jLUOyVE1CXFBiYX\0[ZIhPSCvaX7zJIJ6KHSqaX6gcIEtKEmFNUCgQUAyKM7:TT6= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNFM6PTB{Lze+R4hGVUKOPD;hQi=>
Sf21 NXLrTlh5TnWwY4Tpc44h[XO|YYm= NVTkV2RSPSCvaX7z MVzJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4heDFzMHHsdIhiN3WwdHHn[4VlKHKnY3;tZolv[W62IH\1cIwhdGWwZ4ToJIh2dWGwIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkKxJINmdGy|IIXzbY5oKHCqb4PwbIF1cWS7bHnuc5NqfG:uIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDnZY1u[S1|MmCtRXRRKGGodHXyJFUhdWmwczDifUAtKEmFNUCgQUAyOCEQvF2u MlHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|A{QTVyMj:nQmNpTU2ETEyvZV4>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-MAPK / MAPK ; 

PubMed: 27174919     


AML cell lines and primary AML blasts were treated with increasing doses of IPI-145 (nM) and cultured for 4 hours. Whole cell extracts were prepared and Western blot analysis was conducted for pAKT, pMAPK, and total AKT and MAPK protein levels.

PI3Kγ / PI3Kδ ; 

PubMed: 29522278     


Effects of duvelisib on the PI3K/Akt pathway in B and T cell lines. EBV-negative B cell lines [BJAB and Akata (-)], EBV-positive B cell lines [Akata (+), Mutu I, LCL, Raji, and P3HR1], and EBV-negative T cell line (Jurkat) were treated without (-) or with 1 or 5 μmol/L duvelisib for 48 h. Cell lysates were then immunoblotted for the indicated proteins involved in PI3K/Akt signaling.

27174919 29522278
In vivo IPI-145 (10 mg/kg, p.o.) shows well pharmacokinetics with Cmax and AUC of 390 ng/mL and 137 ng•h/mL in mouse and rat. IPI-145 (10 mg/kg) is active in murine DTH model with ~50% ear swelling. IPI-145 (10 mg/kg) demonstrates dose-dependent effect in rat collagen induced arthritis (CIA) model. IPI-145 prevents inflammation and protects joint bone and cartilage in the rat CIA model. IPI-145 (10 mg/kg,QD) demonstrates activity in rat adjuvant induced polyarthritis model. [1]

Protocol

Solubility (25°C)

In vitro DMSO 83 mg/mL (199.1 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 416.86
Formula

C22H17ClN6O

CAS No. 1201438-56-3
Storage powder
in solvent
Synonyms INK1197
Smiles CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02307461 Completed Drug: IPI-145 (duvelisib)|Drug: IPI-145 Healthy SecuraBio November 2014 Phase 1
NCT02095587 Completed Drug: IPI-145 Hepatic Impairment SecuraBio March 2014 Phase 1
NCT01947777 Completed Drug: IPI-145|Drug: Rifampin Healthy SecuraBio October 2013 Phase 1
NCT01925911 Completed Drug: IPI-145|Drug: Midazolam Healthy SecuraBio August 2013 Phase 1
NCT01836861 Completed Drug: IPI-145 Healthy SecuraBio March 2013 Phase 1
NCT01549106 Completed Drug: IPI-145|Drug: Placebo Healthy Volunteers SecuraBio August 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether IPI-145 S7028 is mixture of two chiral forms, if not, which form is it?

  • Answer:

    S7028 IPI-145 is S form.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Duvelisib|Duvelisib ic50|Duvelisib price|Duvelisib cost|Duvelisib solubility dmso|Duvelisib purchase|Duvelisib manufacturer|Duvelisib research buy|Duvelisib order|Duvelisib mouse|Duvelisib chemical structure|Duvelisib mw|Duvelisib molecular weight|Duvelisib datasheet|Duvelisib supplier|Duvelisib in vitro|Duvelisib cell line|Duvelisib concentration|Duvelisib nmr|Duvelisib in vivo|Duvelisib clinical trial|Duvelisib inhibitor|Duvelisib Angiogenesis inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID